MeiraGTx agreed to buy back a failed eye gene therapy from Johnson & Johnson for $25 million upfront, following the therapy’s Phase 3 setback in X-linked retinitis pigmentosa. The transaction returns rights for bota-vec (botaretigene sparoparvovec) to MeiraGTx as the company pursues next steps for the asset. The deal reflects how gene therapy economics can shift quickly after late-stage disappointments, with companies re-optimizing cost structures and ownership to regain strategic flexibility. MeiraGTx’s move also coincides with additional financing activity across the gene therapy space, signaling continued investor interest despite trial volatility.